Drug Profile
S 38844
Alternative Names: S-38844Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Servier
- Class Cardiovascular therapies; Heart failure therapies
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Heart failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in Germany (PO, Controlled release)
- 01 Jun 2015 IRIS completes a phase II clinical trials in Heart failure in Hungary, Belgium, Slovakia, Estonia, Lithuania and Latvia (PO) (EudraCT2013-003000-39)
- 01 Mar 2014 Phase-II clinical trials in Heart failure in Hungary (PO) (EudraCT2013-003000-39)